Guardant Health, Inc. (GH) Stock
3 members of Congress disclosed 9 trades in GH since 2020: 4 purchases and 5 sales, most recently Jonathan Jackson (purchase, Sep 28, 2026). 7 of the hedge funds AlphaScala tracks reported GH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $243.42M. Company insiders reported 0 open-market buys and 23 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which members of Congress traded Guardant Health, Inc. (GH)?
Most recent: Jonathan Jackson (purchase, Sep 28, 2026); records start May 1, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Jonathan Jackson D-IL · House | 2026-09-28 | purchase | $15k – $50k |
| Sheldon Whitehouse D-RI · Senate | 2025-11-21 | purchase | $1k – $15k |
| Don Beyer D-VA · House | 2022-02-28 | sale | $1k – $15k |
| Don Beyer D-VA · House | 2022-01-13 | sale | $1k – $15k |
| Don Beyer D-VA · House | 2021-12-22 | sale | $1k – $15k |
| Don Beyer D-VA · House | 2020-10-22 | purchase | $1k – $15k |
| Don Beyer D-VA · House | 2020-10-05 | purchase | $1k – $15k |
| Don Beyer D-VA · House | 2020-07-14 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all GH political trades →Which hedge funds own GH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.62M | $243.42M | +76% |
| Citadel Ken Griffin | 1.45M | $217.47M | +87% |
| D.E. Shaw David Shaw | 1.26M | $188.39M | +194% |
| Point72 Steve Cohen | 921K | $138.15M | +32% |
| ARK Invest Cathie Wood | 506K | $75.98M | +4% |
| Marshall Wace | 185K | $27.78M | NEW |
| Bridgewater Associates Ray Dalio | 4K | $636.7K | -68% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Guardant Health, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 16, 26 | Tariq Musa | Director | SELL | 116 | $19K |
| Oct 14, 26 | Azar Alex M Ii | Director | SELL | 69 | $11K |
| Sep 16, 26 | Azar Alex M Ii | Director | SELL | 826 | $145K |
| Sep 16, 26 | Krognes Steve E. | Director | SELL | 1.1K | $192K |
| Sep 16, 26 | Krognes Steve E. | Director | SELL | 3.3K | $579K |
| Sep 16, 26 | Krognes Steve E. | Director | SELL | 1.3K | $229K |
| Sep 16, 26 | Krognes Steve E. | Director | SELL | 971 | $172K |
| Sep 16, 26 | Tariq Musa | Director | SELL | 116 | $20K |
| Sep 15, 26 | Chudova Darya | Chief Technology Officer | SELL | 7.7K | $1.4M |
| Sep 11, 26 | Kalia Kumud | Chief Information Officer | SELL | 4.0K | $632K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →GH price chart
Powered by TradingViewWhat does Guardant Health, Inc. do?
Guardant Health Inc. is a precision oncology company that develops and provides blood and tissue-based tests, along with vast data sets and advanced analytics, to support cancer treatment, monitoring, and early detection. Its core offerings include the Guardant360 family of liquid biopsy tests, such as Guardant360 CDx for companion diagnostics, Guardant360 LDT measuring over 730 genes, Guardant360 Response for therapy monitoring, Guardant360 TissueNext with AI-powered PD-L1 detection, and GuardantINFINITY for comprehensive genomic profiling. The company also provides Guardant Reveal for minimal residual disease detection and the Shield blood test for colorectal cancer screening using genomic and epigenomic signals. Additionally, GuardantOMNI and GuardantINFORM platforms assist biopharmaceutical firms in clinical trials and real-world data analysis. Guardant Health Inc. serves oncologists, healthcare providers, and pharmaceutical partners in the United States and internationally, billing through insurance reimbursements and contracts. Founded in 2011 and headquartered in Palo Alto, California, it plays a pivotal role in advancing non-invasive cancer diagnostics and personalized medicine.